



**FOR IMMEDIATE RELEASE**

**Catabasis Pharmaceuticals to Present at  
International Ataxia Research Conference**

**CAMBRIDGE, MA, March 24, 2015** – [Catabasis Pharmaceuticals](#), Inc., a clinical stage drug development company built on a pathway pharmacology technology platform, today announced that CAT-4001 will be featured in a poster presentation at the upcoming International Ataxia Research Conference. The International Ataxia Research Conference will be held March 25-28, 2015, in Windsor, UK, at the Beaumont Estate.

- Andrew Nichols, Ph.D., vice president, head of research at Catabasis, will present a poster titled “CAT-4001, a Novel Nrf2 Activator and NF-kB Inhibitor, for the Treatment of Friedreich’s Ataxia.” The poster will be presented on Friday, March 27, 2015, from 12:00pm to 2:00pm GMT.

**About CAT-4001**

CAT-4001 is a new chemical entity that modulates the NF-kB pathway and the Nrf2 pathway. NF-kB is a transcription factor that controls cellular response to stress and inflammation. Nrf2 is a transcription factor that regulates cellular response to oxidative stress. Based on its mechanism of action, the Company believes that CAT-4001 has the potential to be used in patients with certain neurodegenerative diseases, particularly ALS or Friedreich’s ataxia.

**About Catabasis**

Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics using its proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. The Company’s SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple targets in one or more related disease pathways. The Company engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its proprietary SMART linkers. The SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. The Company’s initial focus is on treatments for orphan diseases. The Company is also developing other product candidates for the treatment of serious lipid disorders. For more information on the Company’s technology and pipeline of drug candidates, please visit [www.catabasis.com](http://www.catabasis.com).

###

Corporate and Media Contact

Andrea Matthews

Catabasis Pharmaceuticals, Inc.

T: (617)-349-1971

[amatthews@catabasis.com](mailto:amatthews@catabasis.com)